Global DNA Damage Response Drugs Market to Reach $24,848.8 Million by 2030

According to a new market intelligence report by BIS Research titled “Global DNA Damage Response Drugs Market- Analysis and Forecast, 2020-2030,” the global DNA damage response drugs market was valued at $3,595.2 million in 2020 and is anticipated to grow over $24,848.8 million by 2030. The global DNA damage response drugs market is expected to grow at the double-digit compound annual growth rate in the forecast period 2020-2030, aided primarily by the impressive growth in the underlying manufacturing market.

DNA damage response drugs have emerged as one of the most promising cancer therapies in the field of oncology. DNA damage response drugs are primarily utilized to kill cancerous cells while minimizing the impact on non-cancerous cells. These novel anti-cancer drugs have immense potential in terms of offering a selective and efficient tolerated treatment approach for improving cancer survival rates. The development of DNA damage response drugs potentially harnesses various proteins involved in the DNA damage response pathway such as Poly (ADP-ribose) polymerase (PARP), WEE1, Aurora B, ATM kinase, and ATR kinase. Pharmaceutical companies, typically operating in the field of cancer therapeutics, harness this pathway and associated proteins for therapeutic benefits, thereby offering active and maintenance treatment, further increasing progression-free survival (PFS) of patients suffering from advanced cancer.

BIS Research Report - https://bisresearch.com/industry-report/dna-damage-response-drugs-market.html

“North America is the leading contributor in the DNA damage response drugs market and contributed approximately 58.98% to the global market value in 2019. This region is anticipated to grow at a CAGR of 53.52% during the forecast period 2020-2030 and continue dominating the global market in 2030 as well. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 20.76% during the forecast period 2020-2030. The Europe region also contributed a significant share of 18.89% to the global market in 2019 and is anticipated to grow at a CAGR of 19.59% during the forecast period 2020-2030.”

Research Highlights:
• In the DNA damage response drugs market, Talzenna is expected to witness a robust CAGR of 36.45% during the forecast period 2020-2030. However, Lynparza is anticipated to witness the growth of 17.97% during the forecast period.
• AstraZeneca plc is currently the largest shareholder in the global DNA damage response drugs market. This market dominance is attributed to the company’s presence within the market due to its strong geographical footprint along with its broad product pipeline.

This market intelligence report provides a multi-dimensional view of the global DNA damage response drugs market in terms of market size and growth potential. This research report aims at answering various aspects of the global DNA damage response drugs market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Request for a Sample: https://bisresearch.com/requestsample?id=953&type=download

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and enhancements, collaborations and agreements, acquisitions and business expansions. The research report provides a comprehensive analysis of the product sales, manufacturers, and trend analysis by segment, market share, and growth share analysis by companies. Additionally, the report provides a comprehensive, attractive analysis and opportunity analysis for the entire DNA damage response drugs market from 2019 to 2030.
This report is a meticulous compilation of research on more than 20 players in the market ecosystem and draws upon insights from in-depth interviews with key opinion leaders of more than 20 leading and emerging companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players, such as AbbVie Inc., AstraZeneca plc, Bayer AG, BeiGene, Ltd., Clovis Oncology, Debiopharm International SA, Eli Lilly & Company, GlaxoSmithKline plc, Merck KGaA, NMS Group S.p.A, Onxeo SA, Pfizer Inc., Repare Therapeutics, Sierra Oncology, and Zentalis Pharmaceuticals, LLC.

The answers to the following key questions can be derived from this report:
 What are the major market drivers, challenges, and opportunities in the global DNA damage response drugs market?
 What are the underlying structures resulting in the emerging trends within the global DNA damage response drugs market?
 What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
 What are the key regulatory implications in developed and developing regions for the DNA damage response drugs?
 What is the pricing and reimbursement scenario for DNA damage response drugs market?
 What is the implication of the COVID-19 pandemic on the oncology research?
 What are the potential DNA damage response drugs present in the pipeline?
 What is the clinical landscape of DNA damage response drugs market?
 How is each segment of the market expected to grow during the forecast period from 2020 to 2030? What is the anticipated revenue to be generated by each of the segments on the basis of:
o Commercialized Drugs (Lynparza, Talzenna, Zujula, and Rubraca)
o Potential Pipeline Drugs (PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, DNA-PK Inhibitor, and Others)
o Application (Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
 Who are the leading players with significant offerings to the global DNA damage response drugs market? What is the expected market dominance for each of these leading players?
 Which companies are anticipated to be highly disruptive in the future, and why?
 What are the current treatment gaps, and how are DNA damage response drugs anticipated to fill these gaps?
 How does cancer burden impact the development of DNA damage response drugs worldwide?
 What are the unmet needs that are currently being faced?
Key trends targeted in the report:
 What are the emerging trends in the global DNA damage response drugs market?
 How DNA damage response drugs is changing cancer care worldwide??

Contact:
Bhavya Banga
Email: media@bisresearch.com
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ http://bisresearch.com/blog/
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch

About BIS Research:

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.
With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.
Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
What distinguishes BIS Research from the rest of the players is that we don’t simply provide data but also complement it with valuable insights and actionable inputs for the success of our clients.

This release was published on openPR.